Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

November 8, 2012 1:33 pm

"SCT has been granted an option by UHN under which, and prior to April 30, 2013, SCT may conclude the exclusive license provided SCT has secured additional financing sufficient to support its product development operations."